SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
Hodgkin’s lymphoma is a malignant disease with an incidence of 2.2 cases/100,000. The main goals of staging are to measure the extent of disease and associated prognostic factors. Distinct recommendations were produced for initial work-up, first-line therapy of early and advanced stage disease and treatment of relapsed or resistant patients.
KeywordsHodgkin’s lymphoma Clinical guideline Early-stage Advanced-stage Favourable prognosis Unfavourable prognosis
Unable to display preview. Download preview PDF.
- 1.Swerdlow SH, Campo E, Harris NL et al (eds) (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC Press, LyonGoogle Scholar
- 6.Engert A, Franklin J, Eich HT et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25:3495–3502CrossRefPubMedGoogle Scholar
- 8.Engert A, Diehl V, Pluetschow A et al (2009) Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10. Blood (ASH Annual Meeting Abstracts) 114:716Google Scholar
- 9.Straus DJ, Portlock CS, Qin J et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483–3489CrossRefPubMedGoogle Scholar
- 11.Noordijk EM, Thomas J, Foerme MB et al (2005) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (abstract). Proc Am Soc Clin Oncol 16:6505Google Scholar
- 13.Diehl V, Franklin J, Pfistner B et al (2007) 10-year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. 7th International Symposium on Hodgkin Lymphoma, Cologne. Haematologica 92[Suppl 5]:69 [Abstract P114]Google Scholar